KVP Capital Advisors’s Terns Pharmaceuticals TERN Stock Holding History

KVP Capital Advisors’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.2M	Hold	440,000	–	–	17.32%	1
2025 Q4	$17.8M	Buy	+440,000	New	+$10.2M	17.2%	1

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

KVP Capital Advisors's TERN Position: Q1 2026 in Review

KVP Capital Advisors held its Terns Pharmaceuticals (TERN) position steady in Q1 2026 at 440,000 shares worth $23.2M. The position accounts for 17.32% of the portfolio, ranked #1.

KVP Capital Advisors first reported a position in TERN in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

KVP Capital Advisors held 440,000 shares of Terns Pharmaceuticals worth $23.2M as of Q1 2026.
KVP Capital Advisors left its Terns Pharmaceuticals share count unchanged in Q1 2026.
Terns Pharmaceuticals made up 17.32% of KVP Capital Advisors's portfolio in Q1 2026, its #1 holding.
KVP Capital Advisors first reported a position in Terns Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on KVP Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.